Article Text
PDFReview
Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline
Abstract
Infection in people with multiple sclerosis (MS) is of major concern, particularly for those receiving disease-modifying therapies. This article explores the risk of infection in people with MS and provides guidance—developed by Delphi consensus by specialists involved in their management—on how to screen for, prevent and manage infection in this population.
- multiple sclerosis
- infectious diseases
Data availability statement
Data sharing not applicable as no datasets generated and/or analysed for this study.
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
- Update on disease-modifying therapies for multiple sclerosis
- Disease-modifying therapies for multiple sclerosis
- Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications
- Disease modifying therapies for relapsing multiple sclerosis
- Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data
- Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events
- Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis
- Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis
- Disease modification in multiple sclerosis: an update